2026 ASCO Genitourinary Cancers Symposium

BIOTYPE at ASCO GU 2026: Driving Innovation in Uro Oncology

BIOTYPE is heading to San Francisco, where Dr. Abhishek Aich will represent us at the ASCO Genitourinary Cancers Symposium 2026, taking place from February 26 to 28.

This internationally recognized meeting serves as a leading platform for breakthroughs in prostate, bladder, kidney, and testicular cancer. It brings together top experts from around the world and features more than 850 scientific abstracts, offering deep insights into the latest developments shaping the future of uro-oncology.

Our Objectives at ASCO GU 2026:

• Gain insights that will guide the next generation of diagnostic solutions
• Build and strengthen strategic partnerships across the oncology ecosystem
• Stay aligned with the rapidly evolving scientific and clinical landscape in uro‑oncology

During the event, Dr. Abhishek Aich will engage with leading researchers and clinicians. If you are attending and would like to exchange ideas or explore potential synergies, we would be delighted to hear from you.

BIOTYPE’s Commitment to Advancing Uro Oncology Diagnostics

At BIOTYPE, we are dedicated to driving progress in uro-oncology research and diagnostics with a particular focus on bladder cancer.

Our MODAPLEX assay portfolio already enables precise detection of FGFR3 alterations. We are currently expanding it to include gene expression analysis of bladder samples, providing even more comprehensive molecular insights for patient-specific diagnostics.

We look forward to meaningful discussions and new collaborations at ASCO GU 2026.